首页> The Lancet. Oncology> Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

导出 OA

翻译打印收藏纠错

第一作者： Gerhardt,Attard

第一单位： Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.

作者： Gerhardt,Attard ^[1] ; Laura,Murphy ^[2] ; Noel W,Clarke ^[3] ; Ashwin,Sachdeva ^[3] ; Craig,Jones ^[3] ; Alex,Hoyle ^[3] ; William,Cross ^[4] ; Robert J,Jones ^[5] ; Christopher C,Parker ^[6] ; Silke,Gillessen ^[7] ; Adrian,Cook ^[2] ; Chris,Brawley ^[2] ; Clare,Gilson ^[2] ; Hannah,Rush ^[8] ; Hoda,Abdel-Aty ^[6] ; Claire L,Amos ^[2] ; Claire,Murphy ^[2] ; Simon,Chowdhury ^[9] ; Zafar,Malik ^[10] ; J Martin,Russell ^[11] ; Nazia,Parkar ^[2] ; Cheryl,Pugh ^[2] ; Carlos,Diaz-Montana ^[2] ; Carmel,Pezaro ^[12] ; Warren,Grant ^[13] ; Helen,Saxby ^[14] ; Ian,Pedley ^[15] ; Joe M,O'Sullivan ^[16] ; Alison,Birtle ^[17] ; Joanna,Gale ^[18] ; Narayanan,Srihari ^[19] ; Carys,Thomas ^[20] ; Jacob,Tanguay ^[21] ; John,Wagstaff ^[12] ; Prantik,Das ^[22] ; Emma,Gray ^[23] ; Mymoona,Alzouebi ^[24] ; Omi,Parikh ^[25] ; Angus,Robinson ^[26] ; Amir H,Montazeri ^[10] ; James,Wylie ^[3] ; Anjali,Zarkar ^[27] ; Richard,Cathomas ^[28] ; Michael D,Brown ^[3] ; Yatin,Jain ^[3] ; David P,Dearnaley ^[6] ; Malcolm D,Mason ^[29] ; Duncan,Gilbert ^[2] ; Ruth E,Langley ^[2] ; Robin,Millman ^[2] ; David,Matheson ^[30] ; Matthew R,Sydes ^[2] ; Louise C,Brown ^[2] ; Mahesh K B,Parmar ^[2] ; Nicholas D,James ^[6] ; STAMPEDE investigators

作者单位： Cancer Institute, University College London, London, UK; University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk. ^[1] Medical Research Council Clinical Trials Unit, University College London, London, UK. ^[2] Christie and Salford Royal NHS Foundation Trusts, Manchester, UK. ^[3] St James's University Hospital, Leeds, UK. ^[4] Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK. ^[5] Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. ^[6] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; CH and Universita della Svizzera Italiana, Lugano, Switzerland. ^[7] Medical Research Council Clinical Trials Unit, University College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK. ^[8] Guy's and St Thomas' NHS Foundation Trust, London, UK. ^[9] Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK. ^[10] Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. ^[11] Singleton Hospital, Swansea, UK. ^[12] Gloucestershire Oncology Centre, Cheltenham, UK. ^[13] Torbay and South Devon NHS Foundation Trust, Torbay, UK. ^[14] Northern Centre for Cancer Care, Newcastle upon Tyne, UK. ^[15] Queen's University Belfast, Belfast, UK. ^[16] Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK. ^[17] Queen Alexandra Hospital, Portsmouth, UK. ^[18] Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK. ^[19] Kent Oncology Centre, Maidstone, UK. ^[20] Velindre Cancer Centre, Cardiff, UK. ^[21] Royal Derby Hospital, Derby, UK. ^[22] Yeovil District Hospital NHS Foundation Trust, Yeovil, UK. ^[23] Weston Park Hospital, Sheffield, UK. ^[24] East Lancashire Hospitals NHS Trust, Preston, UK. ^[25] Royal Sussex County Hospital, Brighton, UK. ^[26] University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. ^[27] Division of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland; Swiss Group for Clinical Cancer Research, Bern, Switzerland. ^[28] Cardiff University, Cardiff, UK. ^[29] Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK. ^[30]